Journal
LEUKEMIA
Volume 23, Issue 6, Pages 1127-1130Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2008.400
Keywords
advanced-stage; pediatric; lymphoblastic lymphoma
Categories
Funding
- National Cancer Institute [CA 21765]
- American Lebanese Syrian Associated Charities (ALSAC)
Ask authors/readers for more resources
There has been a steady improvement in cure rates for children with advanced-stage lymphoblastic non-Hodgkin's lymphoma. To further improve cure rates whereas minimizing long-term toxicity, we designed a protocol (NHL13) based on a regimen for childhood T-cell acute lymphoblastic leukemia, which features intensive intrathecal chemotherapy for central nervous system-directed therapy and excludes prophylactic cranial irradiation. From 1992 to 2002, 41 patients with advanced-stage lymphoblastic lymphoma were enrolled on the protocol. Thirty patients had stage III and 11 had stage IV disease. Thirty-three cases had a precursor T-cell immunophenotype, five had precursor B-cell immunophenotype and in three immunophenotype was not determined. Out of the 41 patients, 39 (95%) achieved a complete remission. The 5-year event-free rate was 82.9 +/- 6.3% (s.e.), and 5-year overall survival rate was 90.2 +/- 4.8% (median follow-up 9.3 years (range 4.62-13.49 years)). Adverse events included two induction failures, one death from typhlitis during remission, three relapses and one secondary acute myeloid leukemia. The treatment described here produces high cure rates in children with lymphoblastic lymphoma without the use of prophylactic cranial irradiation. Leukemia (2009) 23, 1127-1130; doi: 10.1038/leu.2008.400; published online 5 February 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available